Targovax has announced that the ONCOS-102 and durvalumab trial in patients with advanced peritoneal malignancies has completed enrolment in the colorectal cancer cohort. This phase 1/2 trial is investigating the safety, biologic and anti-tumour activity of ONCOS-102 in combination with Imfinzi (durvalumab, anti-PD-L1) in patients with advanced peritoneal malignancies who have failed prior standard chemotherapy and have histologically confirmed platinum-resistant or refractory epithelial ovarian or colorectal cancer.
Targovax is developing a cancer immunotherapeutic technology with a targeted mechanism of action, making tumours visible to the immune system and educating the immune system to recognize and attack patient specific tumour cells. The technology is based on adenoviruses engineered to kill tumour cells primarily via activation of a systemic, patient-specific anti-tumour immune response. The lead clinical candidate is ONCOS-102.
In October 2020, the pre-defined disease control efficacy threshold in part one in the colorectal cancer cohort was met, and this expansion cohort was opened for recruitment of the part two patients. The clinical and immune activation data are expected to be available first half of 2022. The trial is been conducted at five sites in the US.
"We are very pleased to see that recruitment is completed into this trial. This population of metastatic CRC who have failed prior therapy with peritoneal metastases is a large patient group with no effective available treatment,” said Dr Magnus Jäderberg, Chief Medical Officer of Targovax. “We look forward to seeing the clinical and immune activation data from this novel combination of immunotherapies and hope that it can deliver benefit to the patients."
The trial is a collaboration between Targovax, AstraZeneca, Cancer Research Institute and Ludwig Cancer Research.